Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;55(3):653-659.
doi: 10.1007/s11255-022-03302-5. Epub 2022 Aug 29.

COVID-19 vaccination in peritoneal dialysis patients

Htay Htay  1   2 , Marjorie Wai Yin Foo  3   4 , Sheryl Shien Wen Gan  3   4 , Mathini Jayaballa  3   4 , Elizabeth Ley Oei  3   4 , Mabel Si Hua Tan  5 , Wei Wang  3 , Sin Yan Wu  3 , Chieh Suai Tan  3   4
Affiliations

COVID-19 vaccination in peritoneal dialysis patients

Htay Htay et al. Int Urol Nephrol. 2023 Mar.

Abstract

Background: COVID-19 vaccine is recommended in Peritoneal dialysis (PD) patients, but a paucity of data is available regarding vaccine-related adverse effects among PD patients.

Method: A cross-sectional study was conducted in a single center between October and November 2021. PD patients were provided with the online survey link to participate in the study.

Results: A total of 107 PD patients responded to the survey (55%: male, 79%: Chinese, 40%: > 65 years old). Of these, 95% received the COVID-19 vaccine (77% received two doses and 22% received three doses). Most participants (91%) received Pfizer vaccine. The main source of vaccine information was from the government (48%). The most common reason to receive and refuse vaccines were the perception of the seriousness of COVID-19 infection (63%) and concern about vaccine safety (60%), respectively. After the first dose, 25% of patients developed one or more vaccine-related adverse effects. Common local adverse effect was pain at the injection site (21%), and systemic adverse effects were muscle pain (15%), fatigue (13%). Similar adverse effects were observed with subsequent doses. None of them required hospitalization for vaccine-related adverse effects. Female patients had a higher risk of developing adverse effects than male patients after the first dose (odds ratio: 3.37; 95% confidence interval: 1.25 - 9.08). No such difference was observed in the subsequent dose. Age, race, employment status and history of drug allergy were not associated with the risk of adverse effects.

Conclusions: The COVID-19 vaccine was well-tolerated by most PD patients, but few experienced non-severe adverse effects. All PD patients should be vaccinated against SAR-COV-2 infection.

Keywords: Adverse effects; COVID-19; End-stage kidney disease; Peritoneal dialysis; SAR-COV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Htay Htay has received consultancy fees, speaker’s honoraria and travel sponsorships from Baxter Healthcare and consultancy fees and travel sponsorships from AWAK Technologies, speaker’s honoraria from Fresenius Medical Care, grants from Johnson & Johnson Company, grants from Singhealth NIG, outside the submitted work and Marjorie WY Foo has received grants from National Medical Research Council for the study; consultancy fees and speaker’s honoraria and travel sponsorships from Baxter Healthcare, consultancy fees and travel sponsorships from AWAK Technologies. The other authors have nothing to disclose.

Figures

Fig. 1
Fig. 1
Local adverse effects reported by study participants after COVID-19 vaccination
Fig. 2
Fig. 2
Systemic adverse effects reported by the study participants after COVID-19 vaccination
Fig. 3
Fig. 3
Sources of information for COVID-19 vaccine
Fig. 4
Fig. 4
Sources of information for COVID-19 vaccine
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Weinhandl ED, Wetmore JB, Peng Y, Liu J, Gilbertson DT, Johansen KL. Initial effects of COVID-19 on patients with ESKD. J Am Soc Nephrol. 2021;32(6):1444–1453. doi: 10.1681/ASN.2021010009. - DOI - PMC - PubMed
    1. Robinson BM, Guedes M, Alghonaim M, Cases A, Dasgupta I, Gan L, et al. Worldwide early impact of COVID-19 on dialysis patients and staff and lessons learned: a DOPPS roundtable discussion. Kidney Med. 2021;3(4):619–634. doi: 10.1016/j.xkme.2021.03.006. - DOI - PMC - PubMed
    1. Ikizler TA, Kliger AS. Minimizing the risk of COVID-19 among patients on dialysis. Nat Rev Nephrol. 2020;16(6):311–313. doi: 10.1038/s41581-020-0280-y. - DOI - PMC - PubMed
    1. Htay H, Wong PMPK, Choo RER, Dawood US, Foo MWY, Jayaballa M, et al. Strategies for management of peritoneal dialysis patients in Singapore during COVID-19 pandemic. Ann Acad Med Singapore. 2020;49(12):1025–1028. doi: 10.47102/annals-acadmedsg.2020250. - DOI - PubMed
    1. Strategies regarding COVID-19 in PD patients - International Society for Peritoneal Dialysis [Internet]. [cited 2022 Feb 19]. Available from: https://ispd.org/strategies-covid19/

Substances